Protein expression in CLL explains drug response and clinical outcome. (A) Hazard ratios and P values of known risks plus protein expressions (PRMT5, PYGB, and PES1) using multivariate Cox regression models for predicting TTT. (B) Number of significant associations (FDR = 5%) of protein expression with responses to individual drugs as assessed in an ex vivo drug screen. (C) Exemplary ex vivo drug response and protein expression correlations. (D) Association between ex vivo response to the PI3K inhibitor duvelisib and trisomy 12. (E) Explanatory power of STAT2 protein expression, genetics, and combined STAT2 protein expression and genetics for drug response to cobimetinib. (F) Exemplary ex vivo drug response and protein expression correlation.